Malignant neoplasms of the genitourinary system (DC 7528)

Rating levels

• 100% — You qualify for 100% during ACTIVE genitourinary cancer (kidney, bladder, prostate, testicular, urethral, ureteral, or related GU malignancy). The 100% rating covers the active treatment period AND continues for SIX MONTHS after cessation of all therapeutic procedures (surgery, radiation, chemotherapy, immunotherapy, hormonal therapy). At the 6-month mark a mandatory VA examination is scheduled (see Note 1). The 100% rating is not affected by the prognosis or stage — it applies during active disease and the immediate post-treatment window.
• -1% — At the 6-month mark following cessation of all cancer treatment, the VA must schedule and conduct a mandatory examination. The outcome of that exam (and any subsequent exam) determines whether the 100% rating continues or transitions to a residual rating. ANY reduction from 100% is governed by 38 CFR § 3.105(e), which requires the VA to give written notice of the proposed reduction, provide 60 days for the veteran to submit evidence and request a personal hearing, and provide an additional 60 days notice before reducing pay. These due-process protections cannot be skipped — a reduction without § 3.105(e) compliance is procedurally invalid.
• -1% — If the 6-month mandatory exam (or any later exam) shows NO local recurrence and NO metastasis, the rating transitions from 100% to a residual rating. The residual rating is taken from whichever ladder best matches the predominant residual symptom: voiding dysfunction (urine leakage / urinary frequency / obstructed voiding sub-formulas, 0-60%) if urinary symptoms predominate, OR renal dysfunction (0/30/60/80/100%) if kidney function damage predominates. The reduction itself triggers § 3.105(e) due-process protection; the 100% rating stays in place until that process is complete. If recurrence or metastasis is found, the 100% rating continues without transition.